Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042780 · ClinicalTrials.gov registry record · Phase 2
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03042780 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2 participants.
The verdict
NCT03042780, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas. This is a prospective Phase II open-label trial, stratifying gastroenteropancreatic high grade neuroendocrine carcinomas participants equally into two cohorts (first-line versus beyond first-line).
Interventions
- DRUG FOLFIRINOX
- DRUG Granulocyte colony-stimulating factor (G-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2018-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03042780
The ClinicalTrials.gov registry entry for NCT03042780 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FOLFIRINOX is the first listed.
NCT03042780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03042780 about?
NCT03042780 is a clinical study titled "FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas". The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas. This is a prospective Phase II open-label trial, stratifying gastroenteropancreatic high grade neuroendocrine carcinomas participants equally int...
What is the current status of trial NCT03042780?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-02-01. Estimated completion is 2018-09-07.
What interventions are being tested in trial NCT03042780?
The interventions under investigation include: FOLFIRINOX (DRUG), Granulocyte colony-stimulating factor (G-CSF) (DRUG).
Who is sponsoring clinical trial NCT03042780?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.